To meet growing industry needs for AAV, we have developed the VirusExpress® 293 AAV production platform and established an upstream process for AAV manufacturing. It utilizes a suspension-adapted cell line in chemically defined media using plasmid based, transient transfection. We have advanced the platform by utilizing a high-throughput automated microbioreactor system and a DOE approach. Improvements have been made to the transfection process and cell culture media. Join our webinar to learn how to speed through AAV manufacturing.
In this webinar, you will learn:
<ul>
<li>How our VirusExpress® 293 AAV Production Platform can help speed your gene therapy for patients</li>
<li>How high-throughput screening has enhanced the efficiency of the platform</li>
<li>How improvements to transfection and cell culture media impact performance</li>
<li>How our platform performs with GFP model virus in serotypes AAV2, AAV5, AAV6, and other application data</li>
</ul>

aem-GridColumn aem-GridColumn--default--9

<h2 class="webinar-subtitle">WEBINAR</h2>

Driving the Viral Vector Expressway: Speeding Through AAV Manufacturing

aem-GridColumn aem-GridColumn--default--9 aem-GridColumn--offset--default--0 aem-GridColumn--default--none

aem-GridColumn aem-GridColumn--default--3 aem-GridColumn--offset--default--0 aem-GridColumn--default--none

The production of AAV viral vectors for gene therapy comes with unique upstream challenges. Learn how our HEK platform can solve these challenges.